Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Jain, Ruchi ^a   Dey, Bappaditya ^a   Dhar, Neeraj ^a,d   Rao, Vivek ^a,e   Singh, Ramandeep ^a,f   Gupta, Umesh D ^b   Katoch, V M ^b   Ramanathan, V D ^c   Tyagi, Anil K ^a  

^a UNIVERSITY OF DELHI   (India)

^b NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^d EPFL   (Switzerland)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; NITRIC OXIDE SYNTHASE; RECOMBINANT BCG AG85C; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; RBCG85C VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; GUINEA PIG; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; LUNG FIBROSIS; LUNG GRANULOMA; LUNG TUBERCULOSIS; NONHUMAN; RECEPTOR UPREGULATION; ANIMAL; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM BOVIS; TUBERCULOSIS;

ANIMALIA; CAVIA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; BCG VACCINE; CYTOKINES; FEMALE; GUINEA PIGS; IMMUNOHISTOCHEMISTRY; LUNG; MYCOBACTERIUM BOVIS; RECOMBINANT FUSION PROTEINS; TUBERCULOSIS;

EID: 57349158670     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003869     Document Type: Article

References (46)

1. (2008) Global Tuberculosis Control: surveillance, planning, financing. Geneva: World Health Organization.
2. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344: 1294-1303.
3. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
4. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698-702.
5. Clemens JD, Chuong JJ, Feinstein AR (1983) The BCG controversy. A methodological and statistical reappraisal. JAMA 249: 2362-2369.
6. Trunz BB, Fine P, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-1180.
7. DasGupta SK, Jain S, Kaushal D, Tyagi AK (1998) Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. Biochem Biophys Res Commun 246: 797-804.
8. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97: 13853-13858.
9. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
10. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9: 533-539.
11. Wiker HG, Harboe M, Bennedsen J, Closs O (1988) The antigens of Mycobacterium tuberculosis, H37Rv, studied by crossed immunoelectrophoresis. Comparison with a reference system for Mycobacterium bovis, BCG. Scand J Immunol 27: 223-239.
12. Closs O, Harboe M, Axelsen NH, Bunch-Christensen K, Magnusson M (1980) The antigens of Mycobacterium bovis, strain BCG, studied by crossed immunoelectrophoresis: a reference system. Scand J Immunol 12: 249-263.
13. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, et al. (1996) Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2: 893-898.
14. Dhar N, Rao V, Tyagi AK (2004) Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol 193: 19-25.
15. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
16. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P (2004) Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72: 6148-6150.
17. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, et al. (1997) Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276: 1420-1422.
18. Puech V, Guilhot C, Perez E, Tropis M, Armitige LY, et al. (2002) Evidence for a partial redundancy of the fibronectin-binding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis. Mol Microbiol 44: 1109-1122.
19. Jackson M, Raynaud C, Laneelle MA, Guilhot C, Laurent-Winter C, et al. (1999) Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol Microbiol 31: 1573-1587.
20. Lee BY, Horwitz MA (1999) T-cell epitope mapping of the three most abundant extracellular proteins of Mycobacterium tuberculosis in outbred guinea pigs. Infect Immun 67: 2665-2670.
21. Silver RF, Wallis RS, Ellner JJ (1995) Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J Immunol 154: 4665-4674.
22. D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, et al. (2003) Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71: 483-493.
23. Kumar G, Dagur PK, Singh M, Yadav VS, Dayal R, et al. (2008) Diagnostic potential of Ag85C in comparison to various secretory antigens for childhood tuberculosis. Scand J Immunol 68: 177-183.
24. Mariani F, Cappelli G, Riccardi G, Colizzi V (2000) Mycobacterium tuberculosis H37Rv comparative gene-expression analysis in synthetic medium and human macrophage. Gene 253: 281-291.
25. Dhar N, Rao V, Tyagi AK (2000) Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens of M. tuberculosis. FEMS Microbiol Lett 190: 309-316.
26. Dhar N, Rao V, Tyagi AK (2003) Skewing of the Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system. Immunol Lett 88: 175-184.
27. Singh R, Rao V, Shakila H, Gupta R, Khera A, et al. (2003) Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Mol Microbiol 50: 751-762.
28. Jain S, Kaushal D, DasGupta SK, Tyagi AK (1997) Construction of shuttle vectors for genetic manipulation and molecular analysis of mycobacteria. Gene 190: 37-44.
29. Mitchison DA, Wallace JG, Bhatia AL, Selkon JB, Subbaiah TV, et al. (1960) A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli. Tubercle 41: 1-22.
30. Shakila H, Jayasankar K, Ramanathan VD (1999) The clearance of tubercle bacilli & mycobacterial antigen vis a vis the granuloma in different organs of guinea pigs. Indian J Med Res 110: 4-10.
31. Allen SS, McMurray DN (2003) Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs. Infect Immun 71: 4271-4277.
32. Yamada H, Udagawa T, Mizuno S, Hiramatsu K, Sugawara I (2005) Newly designed primer sets available for evaluating various cytokines and iNOS mRNA expression in guinea pig lung tissues by RT-PCR. Exp Anim 54: 163-172.
33. Turner OC, Basaraba RJ, Orme IM (2003) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 71: 864-871.
34. Basaraba RJ, Izzo AA, Brandt L, Orme IM (2006) Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 24: 280-286.
35. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561-572.
36. Davis AS, Vergne I, Master SS, Kyei GB, Chua J, et al. (2007) Mechanism of inducible nitric oxide synthase exclusion from mycobacterial phagosomes. PLoS Pathog 3: e186.
37. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, et al. (2005) Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 85: 29-38.
38. Ly LH, Russell MI, McMurray DN (2007) Microdissection of the cytokine milieu of pulmonary granulomas from tuberculous guinea pigs. Cell Microbiol 9: 1127-1136.
39. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
40. Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139-145.
41. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178: 2249-2254.
42. Keane MP, Strieter RM (2002) The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res 3: 5.
43. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, et al. (1997) Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 94: 5243-5248.
44. Lowenstein CJ, Padalko E (2004) iNOS (NOS2) at a glance. J Cell Sci 117: 2865-2867.
45. Ly LH, McMurray DN (2008) Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 7: 635-650.
46. Izzo A, Brandt L, Lasco T, Kipnis AP, Orme I (2005) NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinb) 85: 25-28.